Dayton Misfeldt

Dayton Misfeldt General Information

Biography

Mr. Dayton Misfeldt serves as Advisor at Decheng Capital. He serves as Board Member at Upstream Bio. He also served as an Advisor in Bay City Capital, he has a twenty-year history with Bay City Capital primarily investing in biopharmaceutical companies. He brings significant experience spanning multiple market cycles working with management teams with an eye toward strategic decision making, business development, and positioning for exit opportunities. Past investments have included Cadence Pharmaceuticals (acquired by Mallinckrodt), Civitas Therapeutics (acquired by Acorda Therapeutics), Dermira Inc (acquired by Lilly), MAP Pharmaceuticals (acquired by Allergan), Nextwave Pharmaceuticals (acquired by Pfizer), Oculex Pharmaceuticals (acquired by Allergan), and Pharmion Corporation (acquired by Celgene), among others. Prior to Bay City Capital, he was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. He began his career at LifeScience Economics. He received a BA in Economics from the University of California, San Diego.